Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Aspen Neuroscience, Inc. has 1 pending office action in Biotechnology & Pharmaceuticals. The portfolio is associated with 1 distinct examiner and 1 distinct art unit, placing the recorded prosecution activity within a single examination path.
BICKHAM, DAWN MARIE is the busiest examiner and is assigned the pending action. Practitioners can use the focused assignment structure to center claim amendments and supporting arguments on one examiner’s review.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BICKHAM, DAWN MARIE | 1 | 43.9% | +65.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17629766 | METHODS OF IDENTIFYING DOPAMINERGIC NEURONS AND PROGENITOR CELLS | BICKHAM, DAWN MARIE | 2d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17629766 | METHODS OF IDENTIFYING DOPAMINERGIC NEURONS AND PROGENITOR CELLS | BICKHAM, DAWN MARIE | 2d overdue |
| Art Unit | Apps |
|---|---|
| 1685 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17629766 | METHODS OF IDENTIFYING DOPAMINERGIC NEURONS AND PROGENITOR CELLS | BICKHAM, DAWN MARIE | 1685 | §101§103 | Non-Final OA | 2d overdue | Pending | Jan 24, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAspen Neuroscience, Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Dawn Marie Bickham has the most, with 1 of Aspen Neuroscience, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.